

Lumito invites to a webinar in connection with the publication of its third-quarter 2026 report

On Thursday, 29 October 2026, Lumito AB (publ) ("Lumito" or the "Company") will publish its report for the third quarter of 2026. In connection with the publication, shareholders, investors and other interested parties are invited to a webinar on Friday, 30 October at 8:30 a.m. CET.

During the presentation, Sanna Wallenberg, CEO, will provide a brief introduction to Lumito and summarise the key events during the quarter. This will be followed by a presentation of the financial results for the period. Finally, questions submitted in advance to ir@lumito.se will be answered by Sanna Wallenberg and CFO Fata Masic.

The presentation and Q&A session will be recorded and made available on the Company's website afterwards.

Date and time: 30 October 2026 at 8:30 a.m. CET.

Registration for the webinar: <https://events.teams.microsoft.com/event/d81448ad-c8e4-4db9-84c0-6231b0d27701@93b12032-4992-4d22-8a2c-445707f886f0?source=copyLinkOneEventsShareDialog>

For further information, please contact:

CEO Sanna Wallenberg
E-mail: sw@lumito.se
Tel: +46 70 870 01 68

About Lumito

Lumito develops and markets innovative technology that opens new possibilities for advanced analysis of tissue samples in research, drug development and digital pathology.

The Company's patented SCIZYS® platform is based on up-converting nanoparticles (UCNPs) and combines very high detection sensitivity with minimal interfering background. The technology enables the identification and quantitative analysis of specific proteins in tissue, including at low levels that may be difficult to detect using conventional methods. The high signal stability and low background create conditions for more detailed and reproducible tissue analysis.

SCIZYS® has the potential to support the development from predominantly visual and semi-quantitative assessment of biomarkers towards more sensitive, objective and quantitative analysis. This can provide researchers with new tools to understand disease mechanisms, identify biomarkers and develop more personalised treatment strategies.

Lumito's vision extends beyond today's research applications. By enabling more detailed information about biological processes, the Company aims to contribute to the development of precision medicine, where better medicines, diagnostics and more informed treatment decisions may, over time, lead to improved patient outcomes and more efficient use of healthcare resources.

Lumito

Seeing more. Enabling precision medicine.

Towards better patient care.

www.lumito.se

The share is traded on NGM Nordic SME under the name LUMITO.

Attachments

[Lumito invites to a webinar in connection with the publication of its third-quarter 2026 report](#)